McBroom & Associates LLC Sells 441 Shares of Johnson & Johnson (NYSE:JNJ)

McBroom & Associates LLC reduced its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.5% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 29,856 shares of the company’s stock after selling 441 shares during the quarter. Johnson & Johnson accounts for 4.7% of McBroom & Associates LLC’s investment portfolio, making the stock its 9th largest position. McBroom & Associates LLC’s holdings in Johnson & Johnson were worth $5,291,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in JNJ. Family CFO Inc acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $26,000. Steward Financial Group LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $34,000. Joseph P. Lucia & Associates LLC acquired a new stake in Johnson & Johnson during the 1st quarter worth approximately $38,000. Advocacy Wealth Management Services LLC raised its holdings in shares of Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock valued at $41,000 after purchasing an additional 67 shares in the last quarter. Finally, Gibson Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $49,000. 68.78% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 1.6 %

Shares of Johnson & Johnson stock opened at $171.79 on Friday. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.14 and a current ratio of 1.42. The company has a market capitalization of $451.67 billion, a P/E ratio of 25.01, a PEG ratio of 3.29 and a beta of 0.59. The company’s fifty day moving average is $175.41 and its two-hundred day moving average is $174.52.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The company had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period last year, the firm posted $2.48 EPS. Johnson & Johnson’s revenue for the quarter was up 3.0% on a year-over-year basis. Analysts forecast that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.63%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s payout ratio is currently 65.79%.

Insiders Place Their Bets

In other news, CAO Robert J. Decker sold 8,462 shares of Johnson & Johnson stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total value of $1,523,160.00. Following the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the completion of the sale, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of analyst reports. Raymond James raised their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Citigroup reduced their price objective on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group reduced their price objective on shares of Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Finally, SVB Leerink reduced their price objective on shares of Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.